Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Rowland

Showing results (61-70 of 184) with videos related to

Pageof 19
Sort By:
Seminars in Oncology|November 19, 2019
Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitorsAshley M Hopkins, Ganessan Kichenadasse, Ross A McKinnon, et al.
European Urology|July 15, 2020
Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with AtezolizumabAshley M Hopkins, Ganessan Kichenadasse, Christos S Karapetis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2020
Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with AtezolizumabAshley M Hopkins, Ganessan Kichenadasse, Christos S Karapetis, et al.
Journal of the National Cancer Institute|August 27, 2021
RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung CancerAshley M Hopkins, Ganessan Kichenadasse, Jessica M Logan, et al.
Journal of Cancer Research and Clinical Oncology|May 26, 2020
The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenibWarit Ruanglertboon, Michael J Sorich, Jessica M Logan, et al.
British Journal of Cancer|May 27, 2016
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial dataMichael J Sorich, Andrew Rowland, Ganessan Kichenadasse, et al.
Breast Cancer Research and Treatment|August 11, 2019
Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patientsEthan Tang, Andrew Rowland, Ross A McKinnon, et al.
Pharmacology & Therapeutics|September 27, 2020
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotypingJohn O Miners, Andrew Rowland, Jonathan J Novak, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumabAshley M Hopkins, Ganessan Kichenadasse, Chris S Karapetis, et al.
Pharmaceutical Research|February 26, 2017
The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?Mafalda M Dias, Michael J Sorich, Andrew Rowland, et al.
Pageof 19

Showing results (61-70 of 184) with videos related to

Sort By:
Pageof 19
Seminars in Oncology|November 19, 2019
Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitorsAshley M Hopkins, Ganessan Kichenadasse, Ross A McKinnon, et al.
European Urology|July 15, 2020
Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with AtezolizumabAshley M Hopkins, Ganessan Kichenadasse, Christos S Karapetis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2020
Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with AtezolizumabAshley M Hopkins, Ganessan Kichenadasse, Christos S Karapetis, et al.
Journal of the National Cancer Institute|August 27, 2021
RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung CancerAshley M Hopkins, Ganessan Kichenadasse, Jessica M Logan, et al.
Journal of Cancer Research and Clinical Oncology|May 26, 2020
The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenibWarit Ruanglertboon, Michael J Sorich, Jessica M Logan, et al.
British Journal of Cancer|May 27, 2016
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial dataMichael J Sorich, Andrew Rowland, Ganessan Kichenadasse, et al.
Breast Cancer Research and Treatment|August 11, 2019
Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patientsEthan Tang, Andrew Rowland, Ross A McKinnon, et al.
Pharmacology & Therapeutics|September 27, 2020
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotypingJohn O Miners, Andrew Rowland, Jonathan J Novak, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumabAshley M Hopkins, Ganessan Kichenadasse, Chris S Karapetis, et al.
Pharmaceutical Research|February 26, 2017
The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?Mafalda M Dias, Michael J Sorich, Andrew Rowland, et al.
Pageof 19